We have received a favorable determination on our technology from the World Intellectual Property Organization administering the International Patent Cooperative Treaty, which grants us an international priority date for our system. Following this, we have applied for, and been granted, a United States Patent.

We have met with FDA representatives through the Q-submission process to review our concept and discuss implementation methods and regulatory pathways. We received constructive feedback, and have adapted our design to comply with the feedback we received.

We have chosen to partner with Starfish Medical (a leading Canadian device development firm) for formal engineering and product development, as well as regulatory support. Starfish has a strong record of bringing early stage medical devices through designe and regulatory pathways to market.